class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
HEPATOTOXICITY: dose-dependent. EFSA: do not exceed 800mg/day. Cases of acute liver failure with concentrated green tea extracts. Fasted state absorption increased but liver exposure also higher — take with food. Iron chelation: reduces non-haem iron absorption. Drug interactions: anticoagulants (inhibits platelet aggregation), bortezomib (anticancer drug antagonism), nadolol (P-gp substrate — increases exposure). Pregnancy: caffeine contribution from impure extracts.
Primary bioactive catechin of green tea. Inhibits fatty acid synthase, activates AMPK, and has antioxidant and anti-tumour properties in preclinical studies. Hepatotoxicity at high doses documented. EFSA scientific opinion: tolerable upper intake 800mg/day EGCG.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)